We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Analysts on Wall Street project that Astrazeneca (AZN - Free Report) will announce quarterly earnings of $1.14 per share in its forthcoming report, representing an increase of 9.6% year over year. Revenues are projected to reach $14.86 billion, increasing 9.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Astrazeneca metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'BioPharmaceuticals- R&I- Symbicort- World' will reach $707.21 million. The estimate points to a change of +0.3% from the year-ago quarter.
The average prediction of analysts places 'BioPharmaceuticals- R&I- Pulmicort- World' at $100.46 million. The estimate indicates a year-over-year change of -27.2%.
Analysts expect 'BioPharmaceuticals- CVRM- Crestor- World' to come in at $320.68 million. The estimate suggests a change of +5.5% year over year.
According to the collective judgment of analysts, 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' should come in at $142.47 million. The estimate indicates a change of -5% from the prior-year quarter.
The combined assessment of analysts suggests that 'BioPharmaceuticals- R&I- Symbicort- U.S.' will likely reach $302.37 million. The estimate suggests a change of +4.6% year over year.
The collective assessment of analysts points to an estimated 'BioPharmaceuticals- CVRM- Crestor- U.S.' of $9.76 million. The estimate indicates a year-over-year change of -11.3%.
Analysts' assessment points toward 'Oncology- Zoladex- U.S.' reaching $4.27 million. The estimate indicates a change of +6.7% from the prior-year quarter.
The consensus among analysts is that 'Oncology- Tagrisso- U.S.' will reach $813.12 million. The estimate suggests a change of +13.9% year over year.
The consensus estimate for 'BioPharmaceuticals- R&I- Fasenra- U.S.' stands at $307.74 million. The estimate indicates a change of +13.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'BioPharmaceuticals- CVRM- Brilinta- U.S.' should arrive at $60.34 million. The estimate suggests a change of -68.1% year over year.
Analysts forecast 'Oncology- Lynparza- U.S.' to reach $383.55 million. The estimate suggests a change of +10.5% year over year.
Analysts predict that the 'Oncology- Imfinzi- U.S.' will reach $889.38 million. The estimate suggests a change of +30.8% year over year.
Astrazeneca shares have witnessed a change of -3.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #3 (Hold), AZN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Astrazeneca (AZN - Free Report) will announce quarterly earnings of $1.14 per share in its forthcoming report, representing an increase of 9.6% year over year. Revenues are projected to reach $14.86 billion, increasing 9.6% from the same quarter last year.
The consensus EPS estimate for the quarter has been revised 0.3% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Astrazeneca metrics that are commonly tracked and projected by analysts on Wall Street.
It is projected by analysts that the 'BioPharmaceuticals- R&I- Symbicort- World' will reach $707.21 million. The estimate points to a change of +0.3% from the year-ago quarter.
The average prediction of analysts places 'BioPharmaceuticals- R&I- Pulmicort- World' at $100.46 million. The estimate indicates a year-over-year change of -27.2%.
Analysts expect 'BioPharmaceuticals- CVRM- Crestor- World' to come in at $320.68 million. The estimate suggests a change of +5.5% year over year.
According to the collective judgment of analysts, 'BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World' should come in at $142.47 million. The estimate indicates a change of -5% from the prior-year quarter.
The combined assessment of analysts suggests that 'BioPharmaceuticals- R&I- Symbicort- U.S.' will likely reach $302.37 million. The estimate suggests a change of +4.6% year over year.
The collective assessment of analysts points to an estimated 'BioPharmaceuticals- CVRM- Crestor- U.S.' of $9.76 million. The estimate indicates a year-over-year change of -11.3%.
Analysts' assessment points toward 'Oncology- Zoladex- U.S.' reaching $4.27 million. The estimate indicates a change of +6.7% from the prior-year quarter.
The consensus among analysts is that 'Oncology- Tagrisso- U.S.' will reach $813.12 million. The estimate suggests a change of +13.9% year over year.
The consensus estimate for 'BioPharmaceuticals- R&I- Fasenra- U.S.' stands at $307.74 million. The estimate indicates a change of +13.6% from the prior-year quarter.
Based on the collective assessment of analysts, 'BioPharmaceuticals- CVRM- Brilinta- U.S.' should arrive at $60.34 million. The estimate suggests a change of -68.1% year over year.
Analysts forecast 'Oncology- Lynparza- U.S.' to reach $383.55 million. The estimate suggests a change of +10.5% year over year.
Analysts predict that the 'Oncology- Imfinzi- U.S.' will reach $889.38 million. The estimate suggests a change of +30.8% year over year.
View all Key Company Metrics for Astrazeneca here>>>Astrazeneca shares have witnessed a change of -3.4% in the past month, in contrast to the Zacks S&P 500 composite's +2.4% move. With a Zacks Rank #3 (Hold), AZN is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .